CIPROFLOXACIN Drug Patent Profile
✉ Email this page to a colleague
When do Ciprofloxacin patents expire, and what generic alternatives are available?
Ciprofloxacin is a drug marketed by Chartwell, Baxter Hlthcare Corp, Bedford Labs, Dr Reddys, Fresenius Kabi Usa, Hikma Farmaceutica, Hospira, Sentiss, Sun Pharm, Ani Pharms, Dr Reddys Labs Ltd, Endo Operations, Fosun Pharma, Rising, Altaire Pharms Inc, Amring Pharms, Fdc Ltd, Rubicon, Sciegen Pharms Inc, The J Molner, Watson Labs Inc, Aiping Pharm Inc, Amneal, Aurobindo Pharma, Barr, Carlsbad, Hikma, Ivax Sub Teva Pharms, Natco, Nostrum Labs, Pliva, Sun Pharm Inds Ltd, Taro, Teva, Unique, Watson Labs, Yiling, Baxter Hlthcare, Bedford, Inforlife, and Teva Pharms. and is included in fifty-two NDAs.
The generic ingredient in CIPROFLOXACIN is ciprofloxacin hydrochloride. There are thirty-four drug master file entries for this compound. Fifty-six suppliers are listed for this compound. Additional details are available on the ciprofloxacin hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Ciprofloxacin
A generic version of CIPROFLOXACIN was approved as ciprofloxacin hydrochloride by RUBICON on June 9th, 2004.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for CIPROFLOXACIN?
- What are the global sales for CIPROFLOXACIN?
- What is Average Wholesale Price for CIPROFLOXACIN?
Summary for CIPROFLOXACIN
| US Patents: | 0 |
| Applicants: | 41 |
| NDAs: | 52 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 123 |
| Clinical Trials: | 301 |
| Patent Applications: | 1,575 |
| Drug Prices: | Drug price information for CIPROFLOXACIN |
| Drug Sales Revenues: | Drug sales revenues for CIPROFLOXACIN |
| What excipients (inactive ingredients) are in CIPROFLOXACIN? | CIPROFLOXACIN excipients list |
| DailyMed Link: | CIPROFLOXACIN at DailyMed |
See drug prices for CIPROFLOXACIN
Recent Clinical Trials for CIPROFLOXACIN
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Institute of Cancer Research, United Kingdom | Phase 1/Phase 2 |
| Prostate Cancer Foundation | Phase 1/Phase 2 |
| Shanghai Pulmonary Hospital, Shanghai, China | Phase 4 |
Pharmacology for CIPROFLOXACIN
| Drug Class | Fluoroquinolone Antibacterial Quinolone Antimicrobial |
| Mechanism of Action | Cytochrome P450 1A2 Inhibitors |
Medical Subject Heading (MeSH) Categories for CIPROFLOXACIN
Anatomical Therapeutic Chemical (ATC) Classes for CIPROFLOXACIN
Paragraph IV (Patent) Challenges for CIPROFLOXACIN
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| CIPRO | Oral Suspension | ciprofloxacin | 250 mg/5 mL and 500 mg/ 5 mL | 020780 | 1 | 2009-10-16 |
US Patents and Regulatory Information for CIPROFLOXACIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rising | CIPROFLOXACIN HYDROCHLORIDE | ciprofloxacin hydrochloride | TABLET;ORAL | 075817-002 | Jun 9, 2004 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Hospira | CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER | ciprofloxacin | INJECTABLE;INJECTION | 077753-002 | Mar 18, 2008 | AP | RX | No | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Amneal | CIPROFLOXACIN HYDROCHLORIDE | ciprofloxacin hydrochloride | TABLET;ORAL | 075939-004 | Jun 9, 2004 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Rubicon | CIPROFLOXACIN HYDROCHLORIDE | ciprofloxacin hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 075928-001 | Jun 9, 2004 | AT | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Unique | CIPROFLOXACIN HYDROCHLORIDE | ciprofloxacin hydrochloride | TABLET;ORAL | 076639-003 | Sep 10, 2004 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Carlsbad | CIPROFLOXACIN HYDROCHLORIDE | ciprofloxacin hydrochloride | TABLET;ORAL | 076126-003 | Jun 9, 2004 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
